Get access

Randomized Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in Acute Migraine Headache

Authors

  • Brian H. Rowe MD, MSc,

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author
  • Ian Colman PhD,

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author
  • Marcia L. Edmonds MD, MSc,

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author
  • Sandra Blitz MSc,

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author
  • Alan Walker MD,

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author
  • Sheldon Wiens MD

    1. From the School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe and Colman); Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs. Rowe, Blitz, Walker, and Wiens); Department of Psychiatry, Cambridge University, Cambridge, UK (Dr. Colman); Department of Emergency Medicine, University of Western Ontario, London, Ontario, Canada (Dr. Edmonds).
    Search for more papers by this author

  • Conflict of Interest: None

Dr. Brian H. Rowe, Department of Emergency Medicine, University of Alberta, 1G1.42 WMC, 8440-112 Street, Edmonton, Alberta, T6G 2B7, Canada.

Abstract

Objectives.— Migraine headache is a common presentation in the emergency department (ED). Inflammation is thought to play a role in the pathophysiology of migraine and there is conflicting evidence regarding the effect of corticosteroids on reducing early recurrences. We conducted a randomized clinical trial to test the hypothesis that dexamethasone (DEX) reduced headaches after discharge and examine the factors associated with relapse.

Methods.— Consenting adults (18 and older) presenting with acute migraine at 4 EDs were enrolled. In addition to standard intravenous (IV) abortive therapy, using concealed allocation patients were randomized to receive IV DEX (15 mg) or placebo (PLA) in a double-blind fashion. Relapse was defined as a return to the ED, an urgent clinic visit, or a headache that precluded normal activity reported during follow-up telephone interviews 48-72 hours and 7 days after ED discharge. Intention to treat was used for all final analyses.

Results.— A total of 130 patients were randomized; 126 patients are included in the analysis (one patient left prior to treatment and 3 enrolled twice); 64 received DEX and 62 received PLA. Mean age was 35 years, 81% was female; most (77%) suffered from headaches at least monthly. On a 10-point visual analog scale (VAS), the median pain scores were 8 at presentation, and 2 at discharge. At 48-72 hours, relapses occurred in 14/64 (22%) in the DEX group and 20/62 (32%) in the PLA groups (OR = 0.6; 95% CI: 0.3-1.3). By day 7, 18/64 (28%) in the DEX group had relapsed, compared with 25/62 (40%) in the PLA group (OR = 0.6; 95% CI: 0.3-1.3). Controlling for treatment assignment, relapse was more common when headache pain was incompletely relieved (VAS > 2) at ED discharge (OR = 2.2; 95% CI: 1.1-5.4).

Conclusions.— The overall relapse rate differed from those previously reported; however, DEX failed to reduce headache relapses after ED discharge. Relapse was closely associated with incomplete pain relief at discharge. Further research is needed to determine the factors associated with migraine relapse.

Ancillary